Images
Participants
Contact
Raúl Méndez, ICREA researcher and group leader of the Translational Control of Cell Cycle and Differentiation Laboratory at IRB Barcelona, has participated in a study led by Marcos Malumbres, from CNIO, in which a new anticancer strategy is proposed. Involving the collaboration of researchers from CSIC, the Complutense University of Madrid, the University of Santiago de Compostela, and the University of Boston (US), the study published yesterday in Nature Cell Biology has had a strong impact in the media.
These researchers propose to induce an increased need for glucose in tumour cells and cutting off the supply of this polysaccharide to kill them, in combination with drugs such as taxol.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
